The final gapfill payment rate for both the Epi+Gen CHD™ and PrecisionCHD™ tests is higher at $854 compared to the preliminary gapfill payment rates of $350 for Epi+Gen CHD™ and $684.76 for PrecisionCHD™....
Ischemia with No Obstructive Coronary Arteries (INOCA) and Myocardial Infarction with No Obstructive Coronary Arteries (MINOCA) are two underdiagnosed, potentially fatal forms of heart disease that standard...
A customized program for YMCA of East Tennessee members will include educational series “Wisdom Wednesdays,” and access to Cardio Diagnostics’ AI-powered cardiovascular testing at discounted rates...
Growing Adoption of AI-Driven Precision Cardiovascular Medicine Tests Spans Concierge, Functional Medicine, and Primary Care Practices
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Cardio Diagnostics...
Obtaining the payment rates marks a key milestone in gaining broad access to Medicare reimbursement.
EQNX::TICKER_START (NASDAQ:INBS),(NASDAQ:CDIO),(NASDAQ:BIAF),(NASDAQ:TRIB),(NASDAQ:SOBR) EQNX::TICKER_END
From Tonix Pharmaceuticals’ progress on fibromyalgia treatments to Nvidia-backed Recursion Pharmaceuticals, these stocks sparked significant message volume growth on Stocktwits.
Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a precision cardiovascular medicine company, today announced the availability of its CardioInnovate360 TM research-use-only (RUO) solution for biopharmaceutical...
Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a precision cardiovascular medicine company, today announced its PrecisionCHD™ test received Juniper Research’s Future Digital Award for the “Best...